This interview with a US-based payer provides insights into the reimbursement of current and pipeline drugs for NASH, such as factors involved in deciding formulary positioning, pricing, step therapy, and prior authorization. The payer talks about various acceptable net pricing cut-offs for decisions, the ramifications of premium pricing, and possibilities for ways of differential pricing in various, albeit potentially related, indications. This interview was conducted on 31 May 2024. 

If you are a KOL Insight subscriber, you may also access the interview from our KOL Insight portal. 

Biomedtracker’s KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900. 

For our disclosures, please read the Biomedtracker Research Standards.